File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Response to neoadjuvant chemotherapy and hormonotherapy in Chinese women with breast cancer

TitleResponse to neoadjuvant chemotherapy and hormonotherapy in Chinese women with breast cancer
Authors
Issue Date2007
PublisherLippincott Williams & Wilkins.
Citation
The 17th Annual National Interdisciplinary Breast Center Conference: Breast Center Evolution: 2007 and Beyond. In American Journal of Clinical Oncology, 2007, v. 30 n. 4, p. 455-456, abstract no. 32 How to Cite?
AbstractOBJECTIVES: There is an increase use of neoadjuvant chemo-hormonotherapy in the management of breast cancer in the past years. A variety of treatment regimens resulted in different efficacy and tolerability. This study aims to review the local experience of using such modality in a university breast surgical center. METHODS: A retrospective study of patients with breast cancer who received neoadjuvant chemotherapy or hormonal therapy followed by definitive surgery from January 2002 to December 2006 was performed. RESULTS: 91 patients received neoadjuvant chemotherapy during the study period. 53 patients received anthracycline-based regimen (AC only), 37 patients anthracycline and taxane-based regimen (AC + T) and 1 patient had additional Trastuzumab after receiving anthracycline and taxane (AC + TH). The pathologic complete response rates of AC only, AC + T and AC + TH were 9.4% (5/53), 24.3% (9/37) and 100.0% (1/1), respectively. Number of cycles and tumor size were significant factors affecting the pCR rate after neoadjuvant chemotherapy. Grade 4 toxicity was observed in 12.2% of patients during AC treatment and in 15.8% of patients during docetaxel treatment. 81 patients received aromatase inhibitors (AI) as neoadjuvant hormonal therapy. The pCR rate of AI was 1.2% (1/81) and none of the patients experienced grade 3 or 4 toxicity. CONCLUSIONS: The efficacy and tolerability of neoadjuvant therapy are similar in our population as compared with the Western countries. Neoadjuvant chemotherapy could achieve a higher response rate but neoadjuvant hormonotherapy was better tolerated.
Persistent Identifierhttp://hdl.handle.net/10722/182313
ISSN
2015 Impact Factor: 2.977
2015 SCImago Journal Rankings: 0.846

 

DC FieldValueLanguage
dc.contributor.authorSuen, DTK-
dc.contributor.authorKwong, A-
dc.date.accessioned2013-04-22T01:33:14Z-
dc.date.available2013-04-22T01:33:14Z-
dc.date.issued2007-
dc.identifier.citationThe 17th Annual National Interdisciplinary Breast Center Conference: Breast Center Evolution: 2007 and Beyond. In American Journal of Clinical Oncology, 2007, v. 30 n. 4, p. 455-456, abstract no. 32-
dc.identifier.issn0277-3732-
dc.identifier.urihttp://hdl.handle.net/10722/182313-
dc.description.abstractOBJECTIVES: There is an increase use of neoadjuvant chemo-hormonotherapy in the management of breast cancer in the past years. A variety of treatment regimens resulted in different efficacy and tolerability. This study aims to review the local experience of using such modality in a university breast surgical center. METHODS: A retrospective study of patients with breast cancer who received neoadjuvant chemotherapy or hormonal therapy followed by definitive surgery from January 2002 to December 2006 was performed. RESULTS: 91 patients received neoadjuvant chemotherapy during the study period. 53 patients received anthracycline-based regimen (AC only), 37 patients anthracycline and taxane-based regimen (AC + T) and 1 patient had additional Trastuzumab after receiving anthracycline and taxane (AC + TH). The pathologic complete response rates of AC only, AC + T and AC + TH were 9.4% (5/53), 24.3% (9/37) and 100.0% (1/1), respectively. Number of cycles and tumor size were significant factors affecting the pCR rate after neoadjuvant chemotherapy. Grade 4 toxicity was observed in 12.2% of patients during AC treatment and in 15.8% of patients during docetaxel treatment. 81 patients received aromatase inhibitors (AI) as neoadjuvant hormonal therapy. The pCR rate of AI was 1.2% (1/81) and none of the patients experienced grade 3 or 4 toxicity. CONCLUSIONS: The efficacy and tolerability of neoadjuvant therapy are similar in our population as compared with the Western countries. Neoadjuvant chemotherapy could achieve a higher response rate but neoadjuvant hormonotherapy was better tolerated.-
dc.languageeng-
dc.publisherLippincott Williams & Wilkins.-
dc.relation.ispartofAmerican Journal of Clinical Oncology-
dc.titleResponse to neoadjuvant chemotherapy and hormonotherapy in Chinese women with breast canceren_US
dc.typeConference_Paperen_US
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hk-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1097/COC.0b013e318074f916-
dc.identifier.hkuros137435-
dc.identifier.volume30-
dc.identifier.issue4-
dc.identifier.spage455, abstract no. 32-
dc.identifier.epage456-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats